Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Kuypers

Showing results (81-90 of 175) with videos related to

Pageof 18
Sort By:
Radiology|May 3, 2012
Occupational radiation dose: percutaneous interventional procedures on hemodialysis arteriovenous fistulas and graftsSam Heye, Geert Maleux, Raymond H Oyen, et al.
Nederlands Tijdschrift Voor Geneeskunde|November 20, 1971
[10 years of aneurysms of the abdominal aorta]P J Kuypers, J W van Rooy, A G Waterschoot, et al.
Pharmacogenetics and Genomics|October 17, 2014
Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipientsDirk R J Kuypers, Henriette de Loor, Maarten Naesens, et al.
British Journal of Clinical Pharmacology|June 27, 2015
Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocritHylke de Jonge, Thomas Vanhove, Henriëtte de Loor, et al.
Blood Purification|January 11, 2005
A prospective, randomized, double-blind crossover study on the use of 5% citrate lock versus 10% citrate lock in permanent hemodialysis cathetersGert Meeus, Dirk R J Kuypers, Kathleen Claes, et al.
Clinical Pharmacology and Therapeutics|July 15, 2011
In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipientsH de Jonge, H de Loor, K Verbeke, et al.
Pharmacogenomics|September 13, 2013
Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolismHylke de Jonge, Henriette de Loor, Krisitin Verbeke, et al.
Clinical Transplantation|June 5, 2003
The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipientsD R J Kuypers, P Evenepoel, B Maes, et al.
The Journal of Antimicrobial Chemotherapy|December 6, 2008
A single-centre study of adjuvant cidofovir therapy for BK virus interstitial nephritis (BKVIN) in renal allograft recipientsDirk R J Kuypers, Bert Bammens, Kathleen Claes, et al.
British Journal of Clinical Pharmacology|August 4, 2015
Response to 'Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid dose'Thomas Vanhove, Hylke de Jonge, Henriëtte de Loor, et al.
Pageof 18

Showing results (81-90 of 175) with videos related to

Sort By:
Pageof 18
Radiology|May 3, 2012
Occupational radiation dose: percutaneous interventional procedures on hemodialysis arteriovenous fistulas and graftsSam Heye, Geert Maleux, Raymond H Oyen, et al.
Nederlands Tijdschrift Voor Geneeskunde|November 20, 1971
[10 years of aneurysms of the abdominal aorta]P J Kuypers, J W van Rooy, A G Waterschoot, et al.
Pharmacogenetics and Genomics|October 17, 2014
Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipientsDirk R J Kuypers, Henriette de Loor, Maarten Naesens, et al.
British Journal of Clinical Pharmacology|June 27, 2015
Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocritHylke de Jonge, Thomas Vanhove, Henriëtte de Loor, et al.
Blood Purification|January 11, 2005
A prospective, randomized, double-blind crossover study on the use of 5% citrate lock versus 10% citrate lock in permanent hemodialysis cathetersGert Meeus, Dirk R J Kuypers, Kathleen Claes, et al.
Clinical Pharmacology and Therapeutics|July 15, 2011
In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipientsH de Jonge, H de Loor, K Verbeke, et al.
Pharmacogenomics|September 13, 2013
Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolismHylke de Jonge, Henriette de Loor, Krisitin Verbeke, et al.
Clinical Transplantation|June 5, 2003
The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipientsD R J Kuypers, P Evenepoel, B Maes, et al.
The Journal of Antimicrobial Chemotherapy|December 6, 2008
A single-centre study of adjuvant cidofovir therapy for BK virus interstitial nephritis (BKVIN) in renal allograft recipientsDirk R J Kuypers, Bert Bammens, Kathleen Claes, et al.
British Journal of Clinical Pharmacology|August 4, 2015
Response to 'Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid dose'Thomas Vanhove, Hylke de Jonge, Henriëtte de Loor, et al.
Pageof 18